<DOC>
	<DOCNO>NCT01132404</DOCNO>
	<brief_summary>The phase 1 portion study open-label , multicenter , dose-escalation study 1-month depot TAK-448 adult male prostate cancer either gonadotropin release hormone ( GnRH ) therapy might eligible GnRH therapy future . The phase 2 portion study open-label , multicenter , randomize study men prostate cancer confirm testosterone- prostate specific antigen ( PSA ) - lower potential 2 dose level 1-month depot TAK-448 .</brief_summary>
	<brief_title>Study Men With Prostate Cancer Assess Safety , Pharmacokinetics Testosterone-Lowering Efficacy TAK-448</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : Male 40 72 year age Histologicallyconfirmed adenocarcinoma prostate complete primary local treatment least 6 month prior screen Meet laboratory evaluation value screen specify protocol For phase 1 study : Concurrent gonadotropin release hormone ( GnRH ) therapy generally indolent stable disease OR potential candidate GnRH time future . Patients metastatic disease must asymptomatic bone scan positive evidence metastasis . Patients recurrent local disease asymptomatic without bladder , bowel obstructive symptom For phase 2 portion study : evidence progressive prostate cancer , opinion refer physician and/or study investigator warrant initiation GnRH analog therapy . Such patient may either elevate rise PSA least 6 month follow primary local therapy ( y ) evidence metastatic disease previously treat GnRH analog therapy . Provision inform consent phase 1 portion study , willing participate expectation therapeutic benefit Generally fit medical condition , acute chronic medical condition prostate cancer , affect 2year life expectancy Ability understand comply protocol requirement Agreement , even surgically sterilize surgically castrate , practice effective barrier contraception OR abstain heterosexual intercourse Suitable venous access blood sample Patients meet follow exclusion criterion enrol either phase 1 phase 2 portion study : Advanced symptomatic metastatic prostate cancer require immediate GnRH additional hormone therapy require chemotherapy History surgical castration History nonskin cancer , prostate cancer , require active treatment within 2 year screen History cardiac surgery , within previous 6 month plan elective surgery , skin surgery , ensue 6 month Compromise bone marrow function would reduce tolerance repeat blood draw History osteoporosis , unless actively control treatment , history vertebral femoral fracture within past year History seizures currently anticonvulsant medication History major psychiatric illness ( diagnosed psychosis psychiatric illness require hospitalization ) History drug significant alcohol abuse Participation clinical trial receipt experimental therapy within 2 month screen Serious infection within 14 day first dose study drug Known history human immunodeficiency ( HIV ) infection , hepatitis B , hepatitis C infection History significant cardiovascular condition In addition , phase 2 portion study , patient must follow exclusion criterion : Participation phase 1 portion study Prior current use GnRH analog androgen receptor antagonist firstline hormone therapy ( neoadjuvant/adjuvant use ) History use GnRH analog antagonist ( adjuvant neoadjuvant therapy ) within 6 month prior screen History know document primary failure GnRH analog therapy History rise PSA disease progression GnRH analog combine androgen blockade ( CAB ) therapy</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>